AbbVie Stock News

NORTH CHICAGO, Ill. , Oct. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens.

The announcement of a new buildout, as well as developments on the political front, were the factors driving up AbbVie (ABBV 5.54%) stock on Wednesday. The pharmaceutical company's shares rose by nearly 6% in value as a result, during a session when the S&P 500 (^GSPC 0.34%) crept up a comparatively modest 0.3%.

100% tariffs on branded pharmaceutical imports hit today, but exempting U.S. firms like the three stocks below. A new pricing deal promises to stabilize costs, paving the way for pharma growth.

This agreement grants Vizient clients enhanced access to Natrelle®, the broadest selection of breast implant options on the market. IRVINE, Calif.

Stocks in the S&P 500 (^GSPC 0.41%) offer a miserly yield of 1.2% (on average) today. You can do way better than that and still invest in very attractive businesses.

Expansion increases biologics manufacturing for immunology and oncology medicines Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing Furthers longstanding commitment to AbbVie's Massachusetts sites and workforce NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of a $70 million expansion at its AbbVie ...

– BLA based on data from the global Phase 1/2 CADENZA trial NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced submission of a new Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of investigational Pivekimab sunirine (PVEK) for treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera.